ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-MCS / Melanocortin signalling

PT-141

Also known as: Bremelanotide

Approved comparator exists

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

A melanocortin receptor agonist peptide. Bremelanotide is the active in an FDA-approved autoinjector product.

Evidence position

Grade A. The approved product is an autoinjector presentation. A lyophilised vial is not that product. No functional or performance claim is supportable.

What the record does not establish

Published research about a molecule is not a test of any particular vial. Identity, purity, strength and microbiological quality are established by lot-level analytical records tied to a matched sample — not by the literature, and not by the presence of an approved comparator.

Where a lot-level record exists it is published on the evidence page and linked from the product. Where it does not exist, the record says so.

Sources

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.Journal of midwifery & women's health / 2021 NovPMID 34510696 / DOI 10.1111/jmwh.13283
  2. Bremelanotide. / 2012PMID 34436837
  3. Bremelanotide. / 2006PMID 31369224
  4. Bremelanotide: First Approval.Drugs / 2019 SepPMID 31429064 / DOI 10.1007/s40265-019-01187-w
  5. Safety Profile of Bremelanotide Across the Clinical Development Program.Journal of women's health (2002) / 2022 FebPMID 35147466 / DOI 10.1089/jwh.2021.0191

CLINICALTRIALS.GOV / FOUND RECORDS

  1. A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseCOMPLETED / PHASE2 / Palatin Technologies, IncNCT05709444 / DIRECT intervention MATCH: bremelanotide
  2. Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderCOMPLETED / PHASE2 / Palatin Technologies, IncNCT01382719 / DIRECT intervention MATCH: bremelanotide
  3. 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderCOMPLETED / PHASE3 / Palatin Technologies, IncNCT02338960 / DIRECT intervention MATCH: bremelanotide
  4. 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderCOMPLETED / PHASE3 / Palatin Technologies, IncNCT02333071 / DIRECT intervention MATCH: bremelanotide
  5. Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)COMPLETED / PHASE2 / Palatin Technologies, IncNCT00425256 / DIRECT intervention MATCH: bremelanotide

Related compounds

RM-MCS

Melanotan I

Read entry →